Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 2/20 | 0.53 |
| ▸ | KDM4D | Q6B0I6 | 15/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | KDM6A | O15550 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12026411 | 0.85 | CTSK (0.59) | CTSKKDM4DCA1CA2HSD11B1 | |
| SCHEMBL21779949 | 0.85 | CTSK (0.59) | CTSKKDM4DCA1CA2HSD11B1 | |
| SCHEMBL14024975 | 0.85 | CTSK (0.59) | CTSKKDM4DCA1CA2HSD11B1 | |
| SCHEMBL21527239 | 0.84 | CTSK (0.56) | CTSKKDM4DCA1CA2HSD11B1 | |
| SCHEMBL16409127 | 0.82 | CTSK (0.46) | CTSKKDM4DCA1CA2HSD11B1 | |
| SCHEMBL16253370 | 0.80 | CTSK (0.54) | CTSKKDM4DCA1CA2HSD11B1 | |
| SCHEMBL24261283 | 0.79 | CTSK (0.53) | CTSKKDM4DCA1CA2HSD11B1 | |
| SCHEMBL1456569 | 0.79 | CTSK (0.55) | CTSKKDM4DCA1CA2HSD11B1 | |
| SCHEMBL18500471 | 0.78 | CTSK (0.56) | CTSKKDM4DCA1CA2HSD11B1 | |
| SCHEMBL29765193 | 0.77 | CTSK (0.54) | CTSKKDM4DCA1CA2HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150023913-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2015-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150023913-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, EIF2AK2 | CTSK 1909/4885KDM4D 4056/4885CA1 4815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.